prostate health index
Jump to navigation
Jump to search
Indications
- option for prostate cancer screening (FDA-approved in 2012)
Clinical significance
- sensitivity 90%, specificity 30% at cutoff score of 28.6
- false positive rates high
- uncertain whether benefits of screening outweigh potential harms[1]
Procedure
- calculated from measurements of total serum PSA, free PSA, & an isoform of PSA called [-2]proPSA
More general terms
References
- ↑ 1.0 1.1 Brett AS Prostate Health Index: A Relatively New Screening Test for Prostate Cancer NEJM Journal Watch. April 7, 2015 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Loeb S et al. The Prostate Health Index selectively identifies clinically significant prostate cancer. J Urol 2015 Apr; 193:1163. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25463993